PGE2
metabolitePGE2 is an anti-platelet prostanoid whose post-intervention decline reflects resolution of acute platelet activation in STEMI.
Pathway placement
Cascade stepPlatelet adhesion & activation
Confidencemedium
RationaleEicosanoid; anti-platelet prostanoid downregulated post-PCI in STEMI, reflecting altered eicosanoid metabolism.
Also acts inThromboxane / COX-1
Druggability
Not assessed (no mapped human gene target).
Type I vs non-Type I discrimination
ScoresNon-Type-I-associated
R — rupture / Type-I—
C — non-Type-I59
A — assay feasibility42
E — evidence strength86
T1DI (composite)10
Specificity differential (R−C)-44.3
Non-Type-I axis panel
Does this marker also move in each non-Type-I setting? mag 0–3; higher means less Type-I-specific. n/a = no evidence retrieved, which is not the same as no change.
2sepsis / systemic inflammationmag 2
2anemia / acute blood lossmag 2
2hypovolemia / dehydrationmag 1
2tachyarrhythmiamag 2
2hypoxemia / respiratory failuremag 2
2hypertensive emergencymag 1
2high-demand / peri-operative stressmag 2
3sudden cardiac deathn/a
4aPCI-related periproceduralmag 2
4bstent thrombosisn/a
4cin-stent restenosisn/a
5CABG-relatedmag 2
Coverage: 9/12 axes with evidence
Tier: deep-scored (abstract-extracted) · 20 supporting references. See the discrimination table for all markers.
Assay & specimen
Class-level default (no specific cleared assay)— generic method inferred from analyte class; confirm against a specific product insert before use.
Specimen
Serum, plasma or urine
Collection tube
Serum separator (gold/red-top, SST) · Lithium heparin (green-top) · Sterile urine container
Method / principle
LC-MS/MS (targeted metabolomics) or enzymatic colorimetric where available
Reagent / substrate
Stable-isotope-labeled internal standard (MS); or enzyme-coupled Trinder reagent
Platform
LC-MS/MS; some automated chemistry
Turnaround · availability
Send-out / research · Specialized / research
Literature evidence(1)
- Metabolomics reveal dynamic changes in eicosanoid profile in patients with ST-elevation myocardial infarction after percutaneous coronary intervention.Clinical and experimental pharmacology & physiology · 2021 · PMID 33141433 · doi